Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:0
|
作者
Georgios Kontorinis
Jaya Nichani
Simon R. Freeman
Scott A. Rutherford
Samantha Mills
Andrew T. King
Deborah Mawman
Sue Huson
Martin O’Driscoll
D. Gareth Evans
Simon K. W. Lloyd
机构
[1] Central Manchester University Hospitals NHS Foundation Trust,University Department of Otolaryngology
[2] Salford Royal NHS Foundation Trust,Department of Neurosurgery
[3] Salford Royal NHS Foundation Trust,Department of Neuroradiology
[4] Central Manchester University Hospitals NHS Foundation Trust,Department of Genetics Medicine
[5] University of Manchester,School of Cancer and Enabling Services
[6] Southern Teaching Hospital,Department of Otolaryngology, Institute of Neurosciences
来源
European Archives of Oto-Rhino-Laryngology | 2015年 / 272卷
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8–21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p =  0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7–19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients’ age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:7
相关论文
共 50 条
  • [21] Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
    Plotkin, Scott R.
    Stemmer-Rachamimov, Anat O.
    Barker, Fred G., II
    Halpin, Chris
    Padera, Timothy P.
    Tyrrell, Alex
    Sorensen, A. Gregory
    Jain, Rakesh K.
    di Tomaso, Emmanuelle
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (04) : 358 - 367
  • [22] Hearing Improvement after Bevacizumab for Neurofibromatosis Type 2 REPLY
    Plotkin, Scott R.
    Halpin, Chris
    di Tomaso, Emmanuelle
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18) : 1810 - 1811
  • [23] Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions
    Yuan, Ruofei
    Wang, Bo
    Wang, Ying
    Liu, Pinan
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 257 - 276
  • [24] Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results
    Peyre, Matthieu
    Goutagny, Stephane
    Bah, Alpha
    Bernardeschi, Daniele
    Larroque, Beatrice
    Sterkers, Olivier
    Kalamarides, Michel
    NEUROSURGERY, 2013, 72 (06) : 907 - 913
  • [25] Current progress in genomics and targeted therapies for neurofibromatosis type 2
    Hiruta, Ryo
    Saito, Kiyoshi
    Bakhit, Mudathir
    Fujii, Masazumi
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2023, 69 (02) : 95 - 103
  • [26] Clinical management and progress in sudden sensorineural hearing loss during pregnancy
    Xie, Shaobing
    Wu, Xuewen
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (02)
  • [27] Hearing Preservation With the Middle Cranial Fossa Approach for Neurofibromatosis Type 2
    Friedman, Rick A.
    Goddard, John C.
    Wilkinson, Eric P.
    Schwartz, Marc S.
    Slattery, William H., III
    Fayad, Jose N.
    Brackmann, Derald E.
    OTOLOGY & NEUROTOLOGY, 2011, 32 (09) : 1530 - 1537
  • [28] Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas
    Huan Jia
    Ghizlene Lahlou
    Hao Wu
    Olivier Sterkers
    Michel Kalamarides
    Current Otorhinolaryngology Reports, 2021, 9 : 170 - 176
  • [29] Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas
    Jia, Huan
    Lahlou, Ghizlene
    Wu, Hao
    Sterkers, Olivier
    Kalamarides, Michel
    CURRENT OTORHINOLARYNGOLOGY REPORTS, 2021, 9 (02) : 170 - 176
  • [30] Management Strategy of Vestibular Schwannoma in Neurofibromatosis Type 2
    Odat, Haitham Ahmad
    Piccirillo, Enrico
    Sequino, Giuliano
    Taibah, Abdelkader
    Sanna, Mario
    OTOLOGY & NEUROTOLOGY, 2011, 32 (07) : 1163 - 1170